{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:09:44Z","timestamp":1793657384225,"version":"4.5.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00134-020-06091-6","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T07:02:44Z","timestamp":1592809364000},"page":"1524-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":422,"title":["Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E.","family":"Verweij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-9610","authenticated-orcid":false,"given":"Bart J. A.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J. M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-1508","authenticated-orcid":false,"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-9740","authenticated-orcid":false,"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2145-0345","authenticated-orcid":false,"given":"Stijn","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-1285","authenticated-orcid":false,"given":"Thierry","family":"Calandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-4119","authenticated-orcid":false,"given":"Cornelius J.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-8033","authenticated-orcid":false,"given":"Tom","family":"Chiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-5376","authenticated-orcid":false,"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-8627","authenticated-orcid":false,"given":"Nico A. F.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-8167","authenticated-orcid":false,"given":"Bart-Jan","family":"Kullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-1350","authenticated-orcid":false,"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-7785","authenticated-orcid":false,"given":"Cornelia","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8593-8492","authenticated-orcid":false,"given":"Peter Wei-Lun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-8060","authenticated-orcid":false,"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4063","authenticated-orcid":false,"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-7529","authenticated-orcid":false,"given":"M. Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-7127","authenticated-orcid":false,"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-7729","authenticated-orcid":false,"given":"Thomas R.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-4420","authenticated-orcid":false,"given":"Jeroen A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-1213","authenticated-orcid":false,"given":"Lore","family":"Vanderbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3897","authenticated-orcid":false,"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-4894","authenticated-orcid":false,"given":"Frank L.","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"6091_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","volume":"70","author":"C Kosmidis","year":"2015","unstructured":"Kosmidis C, Denning DW (2015) The clinical spectrum of pulmonary aspergillosis. Thorax 70:270\u2013277. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206291","journal-title":"Thorax"},{"key":"6091_CR2","doi-asserted-by":"crossref","unstructured":"Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348\u201359. PMID: 17251531","DOI":"10.1056\/NEJMoa061094"},{"key":"6091_CR3","doi-asserted-by":"crossref","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335\u2013347. PMID: 17251530","DOI":"10.1056\/NEJMoa061098"},{"key":"6091_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L, French Innovative LeukemiaOrganization, (FILO) CLL group (2018) Early-onset invasive aspergillosis and other fungal diseases in patients treated with ibrutinib. Blood 131:1955\u20131959. https:\/\/doi.org\/10.1182\/blood-2017-11-818286","journal-title":"Blood"},{"key":"6091_CR5","doi-asserted-by":"publisher","unstructured":"Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA, on behalf of the European Conference on Infections in Leukemia (ECIL)(2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. In: A position paper by the European conference on infections in Leukemia (ECIL). Leukemia 33:844\u2013862. https:\/\/doi.org\/10.1038\/s41375-019-0388-x","DOI":"10.1038\/s41375-019-0388-x"},{"key":"6091_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.1979.03290400053024","volume":"241","author":"JJ Fischer","year":"1979","unstructured":"Fischer JJ, Walker DH (1979) Invasive pulmonary aspergillosis associated with influenza. JAMA 241:1493\u20131494","journal-title":"JAMA"},{"key":"6091_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","volume":"38","author":"J Wauters","year":"2012","unstructured":"Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, Lagrou K, Wilmer A, Jorens P, Hermans G (2012) Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 38:1761\u20131768. https:\/\/doi.org\/10.1007\/s00134-012-2673-2","journal-title":"Intensive Care Med"},{"key":"6091_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","volume":"196","author":"FL van de Veerdonk","year":"2017","unstructured":"van de Veerdonk FL, Kolwijck E, Lestrade PP, Hodiamont CJ, Rijnders BJ, van Paassen J, Haas PJ, OliveiraDosSantos C, Kampinga GA, Bergmans DC, van Dijk K, de Haan AF, van Dissel J, van Hoeven HG, Verweij PE (2017) Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med 196:524\u2013527. https:\/\/doi.org\/10.1164\/rccm.201612-2540LE","journal-title":"Am J Respir Crit Care Med"},{"key":"6091_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J, Dutch-Belgian Mycosis Study Group (2018) Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 6:782\u2013792. https:\/\/doi.org\/10.1016\/S2213-2600(18)30274-1","journal-title":"Lancet Respir Med"},{"key":"6091_CR10","doi-asserted-by":"publisher","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG (2019) Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis Dec 5. pii: ciz1008. https:\/\/doi.org\/10.1093\/cid\/ciz1008. [Epub ahead of print]","DOI":"10.1093\/cid\/ciz1008"},{"key":"6091_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"S Blot","year":"2012","unstructured":"Blot S, Taccone F, Van Abeele A, Bulpa P, Meersseman W, Brusselaers N, Dimopoulos G, Paiva JA, Misset B, Rello J, Vandewoude K, Vogelaers D, AspICU Study Investigators (2012) A clinical algorithm to diagnose invasive pulmonary aspergillosis in ICU patients. Am J Respir Crit Care Med 186:56\u201364. https:\/\/doi.org\/10.1164\/rccm.201111-1978OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6091_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/135581969900400410","volume":"4","author":"N Black","year":"1999","unstructured":"Black N, Murphy M, Lamping D, McKee M, Sanderson C, Askham J, Marteau T (1999) Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy. 4:236\u2013248","journal-title":"J Health Serv Res Policy."},{"key":"6091_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","volume":"23","author":"AC Kalil","year":"2019","unstructured":"Kalil AC, Thomas PG (2019) Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care 23:258. https:\/\/doi.org\/10.1186\/s13054-019-2539-x","journal-title":"Crit Care"},{"key":"6091_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(18)30496-X","volume":"7","author":"GBD","year":"2017","unstructured":"GBD (2017) Influenza Collaborators (2019) Mortality, morbidity, and hospitalizations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 7:69\u201389. https:\/\/doi.org\/10.1016\/S2213-2600(18)30496-X","journal-title":"Lancet Respir Med"},{"key":"6091_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jcrc.2018.11.013","volume":"50","author":"MC Beumer","year":"2019","unstructured":"Beumer MC, Koch RM, van Beuningen D, OudeLashof AM, van de Veerdonk FL, Kolwijck E, van der Hoeven JG, Bergmans DC, Hoedemaekers CWE (2019) Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J Crit Care 50:59\u201365. https:\/\/doi.org\/10.1016\/j.jcrc.2018.11.013","journal-title":"J Crit Care"},{"key":"6091_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13054-019-2425-6","volume":"23","author":"I Martin-Loeches","year":"2019","unstructured":"Martin-Loeches I, Lemiale V, Geoghegan P, McMahon MA, Pickkers P, Soares M, Perner A, Meyhoff TS, Bukan RB, Rello J, Bauer PR, van de Louw A, Taccone FS, Salluh J, Hemelaar P, Schellongowski P, Rusinova K, Terzi N, Mehta S, Antonelli M, Kouatchet A, Klepstad P, Valkonen M, Landburg PP, Barratt-Due A, Bruneel F, P\u00e8ne F, Metaxa V, Moreau AS, Souppart V, Burghi G, Girault C, Silva UVA, Montini L, Barbier F, Nielsen LB, Gaborit B, Mokart D, Chevret S, Azoulay E, Efraim Investigators and the Nine-I Study Group (2019) Influenza and associated co-infections in critically ill immunosuppressed patients. Crit Care 23:152. https:\/\/doi.org\/10.1186\/s13054-019-2425-6","journal-title":"Crit Care"},{"key":"6091_CR17","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1017\/S0950268811002603","volume":"140","author":"JJ Vehreschild","year":"2012","unstructured":"Vehreschild JJ, Brockelmann PJ, Bangard C, Verheyen J, Vehreschild MJGT, Michels G, Wisplinghoff H, Cornely OA (2012) Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol Infect 140:1848\u20131852. https:\/\/doi.org\/10.1017\/S0950268811002603","journal-title":"Epidemiol Infect"},{"key":"6091_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jfma.2017.06.002","volume":"116","author":"YH Ku","year":"2017","unstructured":"Ku YH, Chan KS, Yang CC, Tan CK, Chuang YC, Yu WL (2017) Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc 116:660\u2013670. https:\/\/doi.org\/10.1016\/j.jfma.2017.06.002","journal-title":"J Formos Med Assoc"},{"key":"6091_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa007","author":"IS Schwartz","year":"2020","unstructured":"Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, Zelyas N, Smith SW (2020) High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta, Canada. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa007","journal-title":"Clin Infect Dis"},{"key":"6091_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/cid\/ciz568","volume":"70","author":"TM Uyeki","year":"2020","unstructured":"Uyeki TM, Ison MG, Wolfe CR, Pavia AT et al (2020) Reply to Verweij et al. Clin Infect Dis 70:350\u2013351. https:\/\/doi.org\/10.1093\/cid\/ciz568","journal-title":"Clin Infect Dis"},{"key":"6091_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","volume":"31","author":"L Vanderbeke","year":"2018","unstructured":"Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J (2018) Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr Opin Infect Dis 31:471\u2013480. https:\/\/doi.org\/10.1097\/QCO.0000000000000504","journal-title":"Curr Opin Infect Dis"},{"issue":"4 Suppl","key":"6091_CR22","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1097\/CCM.0b013e3181c92eeb","volume":"38","author":"MB Rothberg","year":"2010","unstructured":"Rothberg MB, Haessler SD (2010) Complications of seasonal and pandemic influenza. Crit Care Med 38(4 Suppl):e91\u2013e97. https:\/\/doi.org\/10.1097\/CCM.0b013e3181c92eeb","journal-title":"Crit Care Med"},{"key":"6091_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/ciz391","volume":"70","author":"PE Verweij","year":"2020","unstructured":"Verweij PE, Br\u00fcggemann RJM, Wauters J, Rijnders BJA, Chiller T, van de Veerdonk F (2020) Influenza coinfection: be(a)ware of invasive aspergillosis. Clin Infect Dis 70:349\u2013350. https:\/\/doi.org\/10.1093\/cid\/ciz391","journal-title":"Clin Infect Dis"},{"key":"6091_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-020-2808-8","volume":"24","author":"K Thevissen","year":"2020","unstructured":"Thevissen K, Jacobs C, Holtappels M, Toda M, Verweij PE, Wauters J (2020) International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential under-diagnosis outside Europe. Crit Care 24:84. https:\/\/doi.org\/10.1186\/s13054-020-2808-8","journal-title":"Crit Care"},{"key":"6091_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa010","author":"BJA Rijnders","year":"2020","unstructured":"Rijnders BJA, Schauwvlieghe AFAD, Wauters J (2020) Influenza-associated pulmonary aspergillosis: a local or global lethal combination? Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa010","journal-title":"Clin Infect Dis"},{"key":"6091_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina EE, Abril E, Padilla R, Rodr\u00edguez Ru\u00edz C, Ballen A, Frutos-Vivar F, Lorente J\u00c1, Esteban A (2019) Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses 62:673\u2013679. https:\/\/doi.org\/10.1111\/myc.12927","journal-title":"Mycoses"},{"key":"6091_CR27","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/14656566.2019.1626824","volume":"20","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Castaldo N, Carnelutti A (2019) Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother 20:1711\u20131718. https:\/\/doi.org\/10.1080\/14656566.2019.1626824","journal-title":"Expert Opin Pharmacother"},{"key":"6091_CR28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/ciy294","volume":"67","author":"D Kumar","year":"2018","unstructured":"Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Romero P, Aydillo T, Danziger-Isakov L, Limaye AP, Carratala J, Munoz P, Montejo M, Lopez-Medrano F, Farinas MC, Gavalda J, Moreno A, Levi M, Fortun J, Torre-Cisneros J, Englund JA, Natori Y, Husain S, Reid G, Sharma TS, Humar A (2018) A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis 67:1322\u20131329. https:\/\/doi.org\/10.1093\/cid\/ciy294","journal-title":"Clin Infect Dis"},{"key":"6091_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.chest.2018.10.044","volume":"155","author":"S Mulpuru","year":"2019","unstructured":"Mulpuru S, Li L, Ye L, Hatchette T, Andrew MK, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Powis J, Richardson D, Semret M, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA, Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN) (2019) Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest 155:69\u201378. https:\/\/doi.org\/10.1016\/j.chest.2018.10.044","journal-title":"Chest"},{"key":"6091_CR30","unstructured":"Dewi IMW, Cunha C, Gkountzinopoulou ME, Jaeger M, Gresnigt MS, Duarte-Oliveira C, Vanderbeke L, Resendiz A, Br\u00fcggemann R, Verweij PE, Lagrou K, Vande Velde G, de Mast Q, Joosten LAB, Netea MG, van der Ven AJAM, Wauters J, Carvalho A, van de Veerdonk FL. Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. (submitted)"},{"key":"6091_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.04.031","author":"P Koehler","year":"2019","unstructured":"Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA (2019) Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.031","journal-title":"Clin Microbiol Infect"},{"key":"6091_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1007\/s00134-016-4379-3","volume":"42","author":"U Pietsch","year":"2016","unstructured":"Pietsch U, M\u00fcller-H\u00f6cker C, Enzler-Tschudy A, Filipovic M (2016) Severe ARDS in a critically ill influenza patient with invasive pulmonary aspergillosis. Intensive Care Med 42:1632\u20131633. https:\/\/doi.org\/10.1007\/s00134-016-4379-3","journal-title":"Intensive Care Med"},{"key":"6091_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz079","author":"T Mercier","year":"2019","unstructured":"Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, Blijlevens NMA, Vonk AG, Rijnders B, Verweij PE, Lagrou K, Maertens J (2019) Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myz079","journal-title":"Med Mycol"},{"key":"6091_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","volume":"25","author":"PPA Lestrade","year":"2019","unstructured":"Lestrade PPA, Meis JF, Melchers WJG, Verweij PE (2019) Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect 25:799\u2013806. https:\/\/doi.org\/10.1016\/j.cmi.2018.11.027","journal-title":"Clin Microbiol Infect"},{"key":"6091_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:e1\u2013e60. https:\/\/doi.org\/10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"},{"key":"6091_CR36","doi-asserted-by":"crossref","unstructured":"Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177:27\u201334. PMID: 17885264","DOI":"10.1164\/rccm.200704-606OC"},{"key":"6091_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00134-010-2078-z","volume":"37","author":"I Martin-Loeches","year":"2011","unstructured":"Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C, Chiche JD, Barahona D, Villabon M, Balasini C, Pearse RM, Matos R, Rello J, ESICM H1N1 Registry Contributors (2011) Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 37:272\u2013283. https:\/\/doi.org\/10.1007\/s00134-010-2078-z","journal-title":"Intensive Care Med"},{"key":"6091_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S2213-2600(18)30332-1","volume":"6","author":"F Lamoth","year":"2018","unstructured":"Lamoth F, Calandra T (2018) Let\u2019s add invasive aspergillosis to the list of influenza complications. Lancet Respir Med. 6:733\u2013735. https:\/\/doi.org\/10.1016\/S2213-2600(18)30332-1","journal-title":"Lancet Respir Med."},{"key":"6091_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cid\/ciy874","volume":"68","author":"TM Uyeki","year":"2018","unstructured":"Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT (2018) Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 68:895\u2013902. https:\/\/doi.org\/10.1093\/cid\/ciy874","journal-title":"Clin Infect Dis"},{"key":"6091_CR40","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/CCM.0000000000004093","volume":"48","author":"LE Lansbury","year":"2020","unstructured":"Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS (2020) Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med 48:e98\u2013e106. https:\/\/doi.org\/10.1097\/CCM.0000000000004093","journal-title":"Crit Care Med"},{"key":"6091_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00134-017-4951-5","volume":"44","author":"SM Pastores","year":"2018","unstructured":"Pastores SM, Annane D, Rochwerg B, Corticosteroid Guideline Task Force of SCCM and ESICM (2018) Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 44:474\u2013477. https:\/\/doi.org\/10.1007\/s00134-017-4951-5","journal-title":"Intensive Care Med"},{"key":"6091_CR42","unstructured":"https:\/\/www.medicines.org.uk\/emc\/product\/3435\/smpc"},{"issue":"Suppl 1","key":"6091_CR43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Fl\u00f6rl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Br\u00fcggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, L\u00f6ffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sink\u00f3 J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA (2018) Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24(Suppl 1):e1\u2013e38. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002","journal-title":"Clin Microbiol Infect"},{"key":"6091_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","volume":"21\u201322","author":"PE Verweij","year":"2015","unstructured":"Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Br\u00fcggemann RJ, Chowdhary A, Cornely OA, Denning DW, Groll AH, Izumikawa K, Kullberg BJ, Lagrou K, Maertens J, Meis JF, Newton P, Page I, Seyedmousavi S, Sheppard DC, Viscoli C, Warris A, Donnelly JP (2015) International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 21\u201322:30\u201340. https:\/\/doi.org\/10.1016\/j.drup.2015.08.001","journal-title":"Drug Resist Updat"},{"key":"6091_CR45","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/598327","volume":"48","author":"RJ Br\u00fcggemann","year":"2009","unstructured":"Br\u00fcggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441\u20131458. https:\/\/doi.org\/10.1086\/598327","journal-title":"Clin Infect Dis"},{"key":"6091_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cid\/cis437","volume":"55","author":"A Pascual","year":"2012","unstructured":"Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O (2012) Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55:381\u2013390. https:\/\/doi.org\/10.1093\/cid\/cis437","journal-title":"Clin Infect Dis"},{"key":"6091_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201\u2013211. https:\/\/doi.org\/10.1086\/524669","journal-title":"Clin Infect Dis"},{"key":"6091_CR48","doi-asserted-by":"crossref","unstructured":"Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS (2012) The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55:1080\u20131087. PMID: 22761409","DOI":"10.1093\/cid\/cis599"},{"key":"6091_CR49","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.01083-10","volume":"55","author":"PF Troke","year":"2011","unstructured":"Troke PF, Hockey HP, Hope WW (2011) Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 55:4782\u20134788. https:\/\/doi.org\/10.1128\/AAC.01083-10","journal-title":"Antimicrob Agents Chemother"},{"key":"6091_CR50","doi-asserted-by":"crossref","unstructured":"Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532\u20131535. PMID: 17351937","DOI":"10.1002\/cncr.22568"},{"key":"6091_CR51","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ (2012) Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56:4793\u20134799. https:\/\/doi.org\/10.1128\/AAC.00626-12","journal-title":"Antimicrob Agents Chemother"},{"key":"6091_CR52","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/jac\/dku484","volume":"69","author":"M Siopi","year":"2014","unstructured":"Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J (2014) Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother 69:1611\u20131619. https:\/\/doi.org\/10.1093\/jac\/dku484","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"6091_CR53","doi-asserted-by":"publisher","first-page":"e00915-17","DOI":"10.1128\/aac.00915-17","volume":"61","author":"EW Muilwijk","year":"2017","unstructured":"Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Lashof AMLO, Groeneveld GH, van der Hoeven J, Alffenaar JWC, Russel FGM, van de Veerdonk F, Br\u00fcggemann RJM (2017) Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrob Agents Chemother 61(9):e00915-17. https:\/\/doi.org\/10.1128\/aac.00915-17","journal-title":"Antimicrob Agents Chemother"},{"key":"6091_CR54","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/thx.54.11.1047","volume":"54","author":"RJ Boots","year":"1999","unstructured":"Boots RJ, Paterson DL, Allworth AM, Faoagali JL (1999) Successful treatment of post-influenza necrotizing bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin gamma interferon and GM-CSF. Thorax 54:1047\u20131049","journal-title":"Thorax"},{"key":"6091_CR55","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/phar.1764","volume":"36","author":"JM Cottreau","year":"2016","unstructured":"Cottreau JM, Barr VO (2016) A review of antiviral and antifungal use and safety during pregnancy. Pharmacother 36:668\u2013678. https:\/\/doi.org\/10.1002\/phar.1764","journal-title":"Pharmacother"},{"key":"6091_CR56","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s10096-018-3241-7","volume":"37","author":"I Rodriguez-Goncer","year":"2018","unstructured":"Rodriguez-Goncer I, Thomas S, Foden P, Richardson MD, Ashworth A, Barker J, Geraghty CG, Muldoon EG, Felton TW (2018) Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation. Eur J Clin Microbiol Infect Dis 37:1251\u20131257. https:\/\/doi.org\/10.1007\/s10096-018-3241-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6091_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1164\/rccm.201906-1185ST","volume":"200","author":"CA Hage","year":"2019","unstructured":"Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Haydour Q, Knox KS, Kolls JK, Murad MH, Wengenack NL, Limper AH (2019) Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 200:535\u2013550. https:\/\/doi.org\/10.1164\/rccm.201906-1185ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"6091_CR58","doi-asserted-by":"publisher","first-page":"30200","DOI":"10.1016\/S1473-3099(20)30200-0","volume":"S1473\u20133099","author":"FX Lescure","year":"2020","unstructured":"Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y (2020) Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis S1473\u20133099(20):30200. https:\/\/doi.org\/10.1016\/S1473-3099(20)30200-0","journal-title":"Lancet Infect Dis"},{"key":"6091_CR59","doi-asserted-by":"crossref","unstructured":"Alanio A, Delli\u00e8re S, Fodil S, Bretagne S, M\u00e9garbane B (2020) High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients. https:\/\/papers.ssrn.com\/abstract=3575581","DOI":"10.2139\/ssrn.3575581"},{"key":"6091_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13096","author":"P Koehler","year":"2020","unstructured":"Koehler P, Cornely OA, B\u00f6ttiger BW, Dusse F, Eichenauer DA, Fuchs F, Hallek M, Jung N, Klein F, Persigehl T, Rybniker J, Kochanek M, B\u00f6ll B, Shimabukuro-Vornhagen A (2020) COVID-19 associated pulmonary aspergillosis. Mycoses. https:\/\/doi.org\/10.1111\/myc.13096","journal-title":"Mycoses"},{"key":"6091_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJM200307313490519","volume":"349","author":"H Wang","year":"2003","unstructured":"Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W (2003) Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 349:507\u2013508. PMID: 12890854","journal-title":"N Engl J Med"},{"key":"6091_CR62","doi-asserted-by":"crossref","unstructured":"Liao M, Liu Y, Yuan J (2020) The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. MedRxiv","DOI":"10.1101\/2020.02.23.20026690"},{"key":"6091_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/440435a","volume":"440","author":"K Shinya","year":"2006","unstructured":"Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: influenza virus receptors in the human airway. Nature 440:435\u2013436. PMID: 16554799","journal-title":"Nature"},{"key":"6091_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7554\/eLife.57555","volume":"9","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Br\u00fcggemann RJ, van der Hoeven H (2020) Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife 9:55. https:\/\/doi.org\/10.7554\/eLife.57555","journal-title":"Elife"},{"key":"6091_CR65","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.4049\/jimmunol.1303049","volume":"192","author":"K Sun","year":"2014","unstructured":"Sun K, Metzger DW (2014) Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 192:3301\u20133307. https:\/\/doi.org\/10.4049\/jimmunol.1303049","journal-title":"J Immunol"},{"key":"6091_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00134-016-4578-y","volume":"43","author":"I Martin-Loeches","year":"2017","unstructured":"Martin-Loeches I, Schultz JM, Vincent J-L, Alvarez-Lerma F, Bos LD, Sol\u00e9-Viol\u00e1n J, Torres A, Rodriguez A, Sole-Violan J, Torres A, Rodriguez A (2017) Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 43:48\u201358. https:\/\/doi.org\/10.1007\/s00134-016-4578-y","journal-title":"Intensive Care Med"},{"key":"6091_CR67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-020-06091-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T23:10:45Z","timestamp":1624317045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-020-06091-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["6091"],"URL":"https:\/\/doi.org\/10.1007\/s00134-020-06091-6","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PE Verweij reported grants from Gilead Sciences, MSD, Pfizer and F2G, and non-financial support from OLM and IMMY, outside the submitted work. BJA Rijnders was the investigator for studies supported by Gilead Sciences, Janssen-Cilag, MSD, Pfizer, ViiV; has received research grants from Gilead and MSD; was an invited speaker for Gilead, MSD, Pfizer, Jansen-Cilag, BMS; and an advisory board member for BMS, Abbvie, MSD, Gilead, Jansen-Cilag; he received travel support from BMS, Abbvie, MSD, Gilead, Jansen-Cilag. RJM Br\u00fcggemann served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc. All contracts were through Radboudumc, and all payments were invoiced by Radboudumc. E Azoulay has received fees for lectures from Pfizer, Gilead, MSD, Alexion and Baxter. His institution received research support from Fisher&Payckle, Jazz pharma and Gilead. M Bassetti has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioM\u00e8rieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher and The Medicine Company. S Blot received research funding from Pfizer and MSD, travel support from Pfizer, MSD and Gilead, and is an invited speaker for Pfizer and Gilead. T Calandra reported advisory board membership from Astellas, Basilea, Cidara, MSD, Sobi, ThermoFisher and GE Healthcare and data monitoring board membership from Novartis, all outside the submitted work. Fees are paid to its institution. CJ Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems. OA Cornely is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck\/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. T Chiller reported no conflicts of interest. P Depuydt reported no conflicts of interest. DR Giacobbe reported honoraria from Stepstone Pharma GmbH and an unconditional grant from MSD Italia. NAF Janssen reported no conflicts of interest. BJ Kullberg has been a scientific advisor for Amplyx, Cidara and Scynexis. K Lagrou received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, travel support from Pfizer and MSD and speaker fees from Gilead, MSD, FUJIFILM WAKO. C Lass-Florl received research funding from Pfizer, Gilead and Egger, travel support from Pfizer, MSD, and Gilead, and is an invited speaker for Pfizer and Gilead. RE Lewis has received research support from Merck and has served as an invited speaker for Gilead, Cidara. P Wei-Lun Liu has received research grants from MSD, Pfizer, and has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is an advisor to Pfizer, Gilead. O Lortholary has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is a consultant for Gilead, Novartis and F2G. J Maertens reported personal fees and non-financial support from Basilea Pharmaceuticals, Bio-Rad Laboratories, Cidara, F2G Ltd., Gilead Sciences, Merck, Astellas, Scynexis, and Pfizer Inc. and grants from Gilead Sciences, IMMY and OLM. I Martin-Loeches reported no conflicts of interest. MH Nguyen has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this study and served on advisory boards for Astellas, Merck, the Medicines Company, Scynexis and Shionogi. TF Patterson reported grants from Cidara to UT Health San Antonio; personal fees from Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, Toyama and United Medical outside the submitted work. TR Rogers has received grants from Gilead Sciences, lecture honoraria from Gilead Sciences and Pfizer Healthcare Ireland, and advisory board membership with Menarini Pharma. JA Schouten has received unrestricted educational and research grants from MSD and has been an advisor to Pfizer. All contracts were through Radboudumc, and all payments were invoiced by Radboudumc. I Spriet has received unrestricted research grants, speaker fees and travel grants from MSD, Pfizer, Gilead and Cidara. She has served in the advisory board for Cidara. L Vanderbeke is supported by the Flanders Research Foundation (FWO Vlaanderen) through a doctoral fellowship. J Wauters reported grants from Gilead Sciences, MSD and Pfizer, and non-financial support from MSD, outside the submitted work. FL van de Veerdonk has served as an invited speaker for Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}